Hepatic drug metabolism and drug toxicity

Clinical Hepatology

Volumn 2, Issue , 2010, Pages 1211-1221

  Dancygier, Henryk ^a,b   Strassburg, Christian P ^c  

^a GOETHE UNIVERSITY   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889997396     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-04519-6_38     Document Type: Chapter

References (40)

1. Ando Y, Saka H, Asai G, et al (1998) UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9:845-7
2. Bosma PJ, Chowdhury JR, Bakker C, et al (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-5
3. Chouinard S, Tessier M, Vernouillet G, et al (2006) Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol 69:908-20
4. Ciotti M, Basu N, Brangi M, et al (1999) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 260:199-202
5. Dancygier H, Frühauf H (1997) Klinische Pharmakologie der Leberkrankheiten. In: Kuemmerle HP (ed) Klinische Pharmakologie, 4th edn. Ecomed Verlag, Munich, IV-4.11.1, pp 1-77
6. Douillard JY, Cunningham D, Roth AD, et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-7
7. Ebner T, Remmel RP, Burchell B (1993) Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 43:649-54
8. Ehmer U, Vogel A, Schutte JK, et al (2004) Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP- glucuronosyltransferase UGT1A4. Hepatology 39:970-7
9. Folprecht G, Kohne CH (2004) The role of new agents in the treatment of colorectal cancer. Oncology 66:1-17
10. Gagne JF, Montminy V, Belanger P, et al (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-17
11. Gennis MA, Vemuri R, Burns EA, et al (1991) Familial occurrence of hypersensitivity to phenytoin. Am J Med 91:631-4
12. Ghosal A, Hapangama N, Yuan Y, et al (2004) Identification of human UDP-glucuronosyltransferase enzyme (s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-20
13. Gillette JR, Stripp B (1975) Pre- and postnatal enzyme capacity for drug metabolic production. Fed Proc 34:172-8
14. Givens RC, Watkins PB (2003) Pharmacogenetics and clinical gastroenterology. Gastroenterology 125:240-8
15. Hoft RH, Bunker JP, Goodman HI, et al (1981) Halothan hepatitis in three pairs of closely related women. N Engl J Med 304:1023-4
16. Innocenti F, Ratain MJ (2003) Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology 17:52-5
17. Innocenti F, Undevia SD, Iyer L, et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-8
18. Iyer L, King CD, Whitington PF, et al (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-54
19. Karliova M, Treichel U, Malagò M, et al (2000) Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 33:853-5
20. Kawato Y, Aonuma M, Hirota Y, et al (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-91
21. King CD, Green MD, Rios GR, et al (1996) The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP- glucuronosyltransferase 1. 1. Arch Biochem Biophys 332:92-100
22. *3) in Caucasians and Egyptians. Biochem Pharmacol 65:1521-7
23. Kuehl GE, Lampe JW, Potter JD, et al (2005) Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 33:1027-35
24. *2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9:341-9
25. Lankisch TO, Moebius U, Wehmeier M, et al (2006) Gilbert's disease and atazanavir: from phenotype to UDPglucuronosyltransferase haplotype. Hepatology 44:1324-32
26. Lankisch TO, Schulz C, Zwingers T, et al (2008) Gilbert's syndrome and Irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 17:695-701
27. Lankisch TO, Vogel A, Eilermann S, et al (2005) Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 67:1732-39
28. Monaghan G, Ryan M, Seddon R, et al (1996) Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578-81
29. Ogilvie BW, Zhang D, Li W, et al (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of cyp2c8: implications for drug-drug interactions. Drug Metab Dispos 34:191-7
30. Pelekonen O, Kalhala EH, Lormi T K J, et al (1973) Comparison of activities of drug metabolizing enzymes in human fetal and adult livers. Clin Pharmacol Ther 14:840-4
31. Prueksaritanont T, Subramanian R, Fang X, et al (2002) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-12
32. Rotger M, Taffe P, Bleiber G, et al (2005) Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192:1381-6
33. Schenker S, Bay M (1994) Drug disposition and hepatotoxicity in the elderly. J Clin Gastroenterol 18:232-7
34. Strassburg CP, Manns MP (2000) Jaundice, genes and promoters. J Hepatology 33:476-9
35. Tukey RH, Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-14
36. Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616
37. Tukey RH, Strassburg CP, Mackenzie PI (2002) Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62:446-50
38. Weinshilbourn R (2003) Inheritance and drug response. N Engl J Med 348:529-37
39. Woodhouse KW, Mutch E, Williams FM, et al (1984) The effect of age on pathways of drug metabolism in human liver. Age Ageing 13:328-34
40. Zhang D, Chando TJ, Everett DW, et al (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729-39